Table 2 Comparison of ¹⁸F-FDG metabolic parameters and qualitative variables between the relapsed group and the non-relapsed group

Semiquantitative analysis

 Pancreatic lesions

  SUV_max, g/ml

6.0 ± 1.6

5.2 ± 1.1

0.047

  SUVR

2.3(2.0–3.0)

2.0(1.6–2.3)

0.026

  SUV_mean2.5, g/ml

3.4(3.1–3.7)

3.2(2.9–3.6)

0.515

  SUV_mean40%, g/ml

3.3 ± 0.9

2.9 ± 0.7

0.108

  SUV_mean42%, g/ml

3.5 ± 0.9

3.0 ± 0.7

0.069

  MTV_2.5, cm³

70.2(33.9–100.2)

24.9(18.6–72.4)

0.064

  MTV_40%, cm³

80.4(44.7–98.3)

65.8(31.6–136.1)

0.608

  MTV_42%, cm³

74.2(41.0–90.0)

54.8(28.0–126.9)

0.503

  TLG_2.5, g/ml×cm³

234.5 ± 149.1

139.6 ± 102.5

0.020

  TLG_40%, g/ml×cm³

256.9(153.9–343.7)

164.9(90.7–351.2)

0.419

  TLG_42%, g/ml×cm³

236.7(141.3–320.4)

154.1(80.9–330.2)

0.315

Qualitative analysis

 Pancreatic lesions

0.782

  Homogeneous

17(51.5)

10(55.6)

  Heterogeneous

16(48.5)

8(44.4)

0.018

  Diffuse/Multifocal

24(72.7)

7(38.9)

  Segmental/ Focal

9(27.3)

11(61.1)

  Lung, n (%)

12(36.4)

7(38.9)

0.397

  Salivary gland, n (%)

10(30.3)

2(11.1)

0.231

  Biliary duct, n (%)

22(51.2)

18(40.9)

0.212

  Kidney, n (%)

4(12.1)

1(5.6)

0.794

  Total number

2.9 ± 1.8

2.6 ± 1.5

0.637

 Region of lymph nodes

  Cervical, n (%)

9(27.2)

4(22.2)

0.953

  Thoracic, n (%)

17(51.5)

9(50.0)

0.918

  Abdominal, n (%)

15(45.5)

11(61.1)

0.285

  Pelvic, n (%)

4(12.1)

1(5.6)

0.794